RT Journal Article
SR Electronic
T1 HBV and HCV prevalence and treatment eligibility assessment at a primary health facility in Ghana
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.01.24306678
DO 10.1101/2024.05.01.24306678
A1 Madison, Adanusa
A1 Adjei, George
A1 Agyeman, Seth
A1 Banson, Cecil
A1 Nyane, Benjamin
A1 Arthur, Rudolf Aaron
A1 Amoah, Samuel
A1 Halm-Lai, Faustina
A1 Boadi, Dennis
A1 Hagan, Oheneba Charles Kofi
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.01.24306678.abstract
AB Background Viral hepatitis continues to be of global public health importance, especially hepatitis B and C. Hepatitis B and C account for most of the mortality and morbidity attributable to these viral infections. There is lack of accessibility to diagnostic tools, assessment for the eligibility for treatment and treatment in most LMICs, including Ghana. Assessment for HBV treatment is expensive and not widely available throughout Ghana. TREAT-B, a new, affordable and widely available assessment tool for HBV treatment eligibility, offers a cost-effective alternative to the international and local guidelines currently in use.Aim To determine the prevalence of HBV and HCV in a cohort of patients and to assess the HBV infected for treatment eligibility.Materials and methods A cross-sectional study of individuals diagnosed with hepatitis B infection was undertaken to assess their eligibility for treatment using local and international treatment guidelines. An additional retrospective review of records of patients screened for hepatitis B and C viruses over the period was undertaken. Questionnaires on socio-demographic were self-administered. Blood was taken for haematological analysis, liver function test, hepatitis B serological tests and DNA extraction for hepatitis B genotyping and drug sensitivity determination.Results From the retrospective review, 3358 individuals had complete data for further analysis. Prevalence for HBV and HCV was estimated at 4.3% and 1.9% respectively. Males were 3 times more likely to be HBV positive compared to females (AOR=2.8, 95% CI: 1.8-4.2, p-value < 0.001). Those who were born after the introduction of after the UCVHB had higher odds of having HBV compared to those who were born before (AOR=3.6, 95% CI: 2.5-5.3, p-value < 0.001). Assessment of 74 HBV positive patients found, 20%, 9.5%, 4.7% and 4.7% were eligible for treatment according to the TREAT-B, the WHO simplified, Ghanaian and AASLD guidelines respectively.Conclusion The burden of HBV and HCV infections remain high in Ghana and policies must be implemented to treat individuals eligible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by University of Cape Coast Directorate of research, innovation and consultancyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Cape Coast Institutional Review Board Ethical approval was grantedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data from which the manuscript was derived has been deposited in the Mendeley Data (Hagan, Oheneba C K (2024), “Cape Coast Hepatitis B and C Screening and treatment eligibility assessment dataset”, Mendeley Data, V1, doi: 10.17632/4d6xynfdsy.1) Sequences from the Sanger sequencing has been deposited in the Genbank.